The history of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial launch generated significant returns, the lapse of its patent opened the floodgates to cheaper alternatives, https://bookmarkgenious.com/story21776473/sildenafil-and-pharma-a-risky-investment